Cargando…

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

BACKGROUND: Respiratory syncytial virus (RSV) causes bronchiolitis and pneumonia in neonates and infants. RSV vaccination during pregnancy could boost preexisting neutralizing antibody titers, providing passive protection to newborns. METHODS: Two observer-blinded, controlled studies (RSV F-020 [cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beran, Jiři, Lickliter, Jason D, Schwarz, Tino F, Johnson, Casey, Chu, Laurence, Domachowske, Joseph B, Van Damme, Pierre, Withanage, Kanchanamala, Fissette, Laurence A, David, Marie-Pierre, Maleux, Koen, Schmidt, Alexander C, Picciolato, Marta, Dieussaert, Ilse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913599/ https://www.ncbi.nlm.nih.gov/pubmed/29401325 http://dx.doi.org/10.1093/infdis/jiy065

Ejemplares similares

Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women
por: Schwarz, Tino F, et al.
Publicado: (2021)

Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial
por: Schwarz, Tino F, et al.
Publicado: (2019)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
por: Langley, Joanne M., et al.
Publicado: (2017)

Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants
por: Steff, Ann-Muriel, et al.
Publicado: (2020)

Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results( )
por: Withanage, Kanchanamala, et al.
Publicado: (2021)

1239. Different Dose Levels of a Respiratory Syncytial Virus Maternal Vaccine Candidate (RSVPreF3) Administered to Non-pregnant Women in a Randomized Clinical Trial Are Immunogenic and Well Tolerated
por: Schwarz, Tino, et al.
Publicado: (2020)

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector–Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults
por: Cicconi, Paola, et al.
Publicado: (2020)

Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings( )
por: Langley, Joanne M, et al.
Publicado: (2022)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial
por: Bebia, Zourab, et al.
Publicado: (2023)

Obesity, Diabetes, and the Risk of Invasive Group B Streptococcal Disease in Nonpregnant Adults in the United States
por: Pitts, Samantha I, et al.
Publicado: (2018)

Factors Associated With Coronavirus Disease 2019 Vaccine Uptake Among Pregnant Women and Nonpregnant Women of Reproductive Age in Jamaica
por: Pinkney, Jodian A, et al.
Publicado: (2023)

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial
por: Leroux-Roels, Geert, et al.
Publicado: (2018)

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine
por: Jordan, Elke, et al.
Publicado: (2023)

2855. Respiratory Syncytial Virus Neutralizing Antibodies in Cord Blood and Serum from Infants up to 2 Years of Age in a Multinational Prospective Study
por: Domachowske, Joseph B, et al.
Publicado: (2019)

Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness
por: Falsey, Ann R., et al.
Publicado: (2014)

Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults
por: August, Allison, et al.
Publicado: (2022)

Transmission of Respiratory Syncytial Virus Infection Within Families
por: Heikkinen, Terho, et al.
Publicado: (2014)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
por: Guiñazú, Javier Ruiz, et al.
Publicado: (2020)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study
por: Erdem, Rahsan, et al.
Publicado: (2023)

Epidemiology and Characteristics of Respiratory Syncytial Virus Pneumonia in Critically Ill Adults
por: Kim, Taeeun, et al.
Publicado: (2023)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study
por: Paris, Robert, et al.
Publicado: (2023)

Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9–14 Years: A Randomized Trial
por: Huang, Li-Min, et al.
Publicado: (2017)

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
por: De Coster, Ilse, et al.
Publicado: (2021)

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012
por: Pastula, Susan T., et al.
Publicado: (2017)

Recurrent Respiratory Syncytial Virus Infection in a CD14-Deficient Patient
por: Besteman, Sjanna B, et al.
Publicado: (2022)

Estimation of the Number of Respiratory Syncytial Virus–Associated Hospitalizations in Adults in the European Union
por: Osei-Yeboah, Richard, et al.
Publicado: (2023)

Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children
por: Karron, Ruth A, et al.
Publicado: (2020)

Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics
por: Suryadevara, Manika, et al.
Publicado: (2021)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

Phase 1 Safety and Immunogenicity Study of a Quadrivalent Seasonal Flu Vaccine Comprising Recombinant Hemagglutinin-Flagellin Fusion Proteins
por: Tussey, Lynda, et al.
Publicado: (2016)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study
por: Van Damme, Pierre, et al.
Publicado: (2019)

Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study)
por: Hartmann, Katrin, et al.
Publicado: (2022)

Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis
por: Onwuchekwa, Chukwuemeka, et al.
Publicado: (2023)

Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children
por: Englund, Janet A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_togponfm2n7kp0kidt0enm8g6v